BICYCLO\[1.1.1\]PENTANES AS PHENYL BIOISOSTERES
There is a tension that runs through most lead optimisation programmes. Aromatic rings often contribute significantly to potency, but they can also increase metabolic liability, plasma protein binding, and molecular flatness. Removing a phenyl group usually costs binding. Keeping it often costs selectivity or developability somewhere else. Bicyclo\[1.1.1\]pentane \(BCP\), one of the best-established saturated bioisosteres of the para-substituted phenyl ring, offers a way through that tension that has become genuinely mainstream over the last decade. Its geometry is well understood: a compact, rigid three-dimensional structure with a vector relationship between the bridgehead carbons that closely mimics the para relationship across a phenyl ring. The distance between attachment points shorter and the directionality of substitution is preserved, allowing BCPs to function as effective phenyl bioisosteres in many binding contexts. What it changes substantially is the physicochemical profile. Because BCPs are saturated rather than aromatic, they can reduce susceptibility to certain aromatic oxidative metabolic pathways while increasing molecular saturation. LogD often decreases, aqueous solubility tends to improve, and a planar aromatic ring is replaced by a rigid three-dimensional scaffold with defined geometry. In CNS programmes, these changes have often provided opportunities to better balance permeability, metabolic stability, and physicochemical properties, although the outcome remains highly context dependent. Our BCP building block range is ideal for direct use as phenyl replacements in lead optimisation. Where in your programmes have BCP replacements delivered the most consistent gains? Further reading: 1. Investigation of a Bicyclo\[1.1.1\]pentane as a Phenyl Replacement within an LpPLA2 Inhibitor https://lnkd.in/ej5UCUta 2. Rapid access to 3-substituted BCPs https://lnkd.in/eXUk4ssu 3. BCP-based lipids for mRNA delivery https://lnkd.in/eW2KgApZ